HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $60
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $65 to $60.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $65 to $60.
